JS Link제이에스링크

JS Link's shares have fallen sharply over the past three months while the company remains loss-making on a trailing basis.

JS Link, a KOSDAQ-listed firm working in genome analysis, molecular diagnostics and, more recently, permanent magnets, reported trailing twelve-month revenue of ₩22.8B against an operating loss of ₩14.4B as of H1 2026. The share price is ₩18,630, down 42.1% over one month and 37.8% over three months, though it remains well above its 52-week low of ₩13,860. Earnings and cash flow are negative, and the data does not include a fair value estimate or analyst views.

What stands out

• Trailing operating margin is -63.2% and net margin is -23.3%, and 2025 net loss widened to ₩16.4B from ₩10.8B in 2024.
• Revenue grew 21.4% in 2025 to ₩19.3B after falling 27.5% in 2024, so top-line results have been volatile.
• Cash of ₩72.2B exceeds borrowings of ₩54.1B, but trailing free cash flow was -₩45.2B.
• Valuation is not meaningful on earnings, with price-to-book at 6.7 and price-to-sales at 30.6; the company pays no dividend.
• Foreign ownership rose from 2.6% to 4.9% over the past 60 days, while 20-day flows show institutions net buyers and retail net sellers.
• Recent filings include a CEO change on 2026-09-09, several 5%+ holding reports in October, and a half-year report in August; the latest news headline covers an MOU with Turkey's ATES Wind Power.

What to watch

• Next periodic results and whether operating losses narrow from the H1 2026 trend.
• Follow-up on the CEO change and the amended sales contract and share acquisition filings from September.
• Progress on the permanent magnet business and the cash burn needed to fund it, as the data does not give details on either.